Chemomab Therapeutics Stock (NASDAQ: CMMB)

Chemomab Therapeutics (NASDAQ:CMMB) Stock, Quote.Headers.trade-ideas

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

movers image

News

Intraday Update

Markets

Movers

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Health Care

Offerings

General

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics&#39; CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

What&#39;s Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics Ltd

Morgan Stanley analyst Ravi Shanker downgrades FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Equal-Weight to Underweight and lowers the price target from $215 to $200.

Downgrades

Price Target

Analyst Ratings

Morgan Stanley Downgrades FedEx to Underweight, Lowers Price Target to $200

Ahead of the 2024 presidential election, the front yard of Warren Buffett in Omaha, Nebraska, could play a pivotal role in shaping the outcome.
What Happened: In Nebraska's 2nd Congressional District, a single electoral vote could be crucial. Neighbors are closely watching to see if a blue-dot sign appears outside Buffett's home. These signs, part of a grassroots effort, symbolize Democratic solidarity in a predominantly Republican area, The Wall Street Journal <a href="https://www.wsj.com/us-news/blue-dot-signs-warren-buffett-presidential-race-a9a26579">report</a> on Friday.
Buffett's history of supporting Barack Obama and Hillary Clinton has raised hopes among Democrats. One neighbor even sent Buffett a handwritten letter urging him to display a blue-dot sign. His daughter, Susan Buffett, already has two signs in her yard.
The blue-dot campaign was initiated by Jason Brown, who lives near Buffett. Inspired by the Democratic National Convention, Brown's idea has led to thousands of signs being distributed across Omaha. The signs are especially concentrated in Buffett's upscale neighborhood.
See Also: <a href="https://www.benzinga.com/news/24/09/40950674/data-scientist-who-called-2020-election-correctly-says-its-gone-from-drastic-landslide-in-trumps-dir?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist Who Called 2020 Election Correctly Says Its Gone From &#8216;Drastic Landslide In Trump&#8217;s Direction To A drastic landslide For Harris&#8217;</a>
Brown and his wife, Ruth Huebner-Brown, have distributed over 5,000 signs and plan to produce more. They request a $10 contribution to cover costs and pledge to donate any profits. Despite the grassroots effort, Buffett has not commented on whether he will display a sign.
Why It Matters: The influence of Warren Buffett in political circles has been significant over the years. In 2017, Buffett surprisingly <a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr">expressed support for Donald Trump'</a>s cabinet choices, indicating his pragmatic approach to politics. This bipartisan stance adds weight to his potential endorsement in the current election.
Recently, Elon Musk speculated that this time, Buffett might be <a href="https://www.benzinga.com/general/politics/17/01/8927406/trumps-newest-unlikely-ally-warren-buffett">positioning for a Kamala Harris win</a>, given his $277 billion cash reserve. This speculation comes amid a divided business community, with hedge fund manager John Paulson warning of a market exit if Harris wins. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump In Trouble: Vice President Harris Has Record 6-Point Lead In 2024 Election Poll After Debate, Posts Highest Rankings In Key Demographics</a></li>
</ul>
Image via Flickr
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

Trump Vs. Harris: Will Warren Buffett Display A Blue Or Red Dot In His Front Yard? Neighbors Wait To See Who The Oracle Of Omaha Is Supporting

The European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy&nbsp;(semaglutide 2.4 mg) label.
The label <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=170500" rel="noreferrer noopener">update</a> incorporates data showing that Wegovy, when added to the standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40813963/ozempic-maker-novo-nordisk-touts-encouraging-data-from-new-obesity-pill-showing-double-weight-los" rel="noreferrer noopener">Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy</a>
Heart failure affects at least 64 million people worldwide and is especially prevalent in obese and/or type 2 diabetes patients.
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart failure, comprising approximately 50% of all heart failure cases.
The positive opinion is based on the results from the STEP HFpEF and STEP HFpEF-DM trials.
In both trials, Wegovy&nbsp;demonstrated greater reductions in heart failure-related symptoms, improvements in physical limitations, and weight loss compared to placebo.
The label update also incorporates data that showed that participants receiving Wegovy&nbsp;achieved a greater increase in exercise function, as measured by the difference in 6-minute walking distance (6MWD) from baseline to week 52, compared to those receiving placebo.
The recommendation to incorporate the data from the STEP HFpEF trials adds to the recent Wegovy&nbsp;EMA label update, which included data from the SELECT landmark trial to reflect the risk reduction of heart attack, stroke, and cardiovascular death.
With the positive opinion from the CHMP, Novo Nordisk expects implementation of the EU label update shortly, following a linguistic review process by the EMA.
As communicated earlier this year, Novo Nordisk will resubmit to the FDA in 2025 to include data from the STEP HFpEF trials in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40229407/novo-nordisk-withdraws-wegovy-fda-heart-failure-submission-terminates-development-of-two-early-st" rel="noreferrer noopener">Wegovy&nbsp;label in the U.S</a>.
In its quarterly earnings report, Novo Nordisk announced that it had submitted the Wegovy STEP HFpEF trials data for regulatory review in the U.S. and EU in January 2024. However, following discussions with the FDA, the company withdrew the submission.
Novo Nordisk said it plans to resubmit the file in early 2025, incorporating additional data, including findings from the kidney outcomes trial for its once-weekly injectable semaglutide 1.0 mg.
Price Action: NVO stock is down 0.42% at $134.32 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40946305/abbott-laboratories-attractive-valuation-ranks-it-among-top-large-cap-medtech-compa" target="_blank" rel="noreferrer noopener">Abbott Laboratories&#8217; Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst</a>.</li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure

Morgan Stanley analyst Dara Mohsenian downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and maintains the price target from $185 to $185.

Morgan Stanley Downgrades PepsiCo to Equal-Weight, Maintains Price Target to $185

ATNM

Actinium Pharmaceuticals Publishes Phase 3 SIERRA Trial Results Of Iomab-B In Journal Of Clinical Oncology, Highlights Success In Achieving Complete Remission And Event-Free Survival

Morgan Stanley analyst Rashad Kawan maintains Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) with a Overweight and raises the price target from $9.9 to $10.95.

Morgan Stanley Maintains Overweight on Haleon, Raises Price Target to $10.95

Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) has been outperforming its dog-themed meme coin rivals, prompting calls for a surge to $10 billion and beyond.
What Happened: Pseudonymous crypto trader SomSpencer declared the arrival of the "meme season" in the crypto market, emphasizing the importance of PEPE as a key indicator. 
He stated that the meme coin has broken out and described Pepe as "the &#8220;meme index" for this crypto cycle, suggesting that its performance is a reliable indicator of the market&#8217;s risk appetite.
The trader <a href="https://x.com/SomSpencer1771/status/1836790093975031916">anticipates</a> PEPE to set new all-time highs in the current quarter, possibly before the election. He also predicts a significant liquidity shift from PEPE as it approaches a $10B billion market cap, with liquidity likely to rotate into midcaps and microcaps.
He concluded by stating, "No one is bullish enough. It&#8217;s time for an up-only market."
Another trader <a href="https://x.com/cryptojourneyrs/status/1836868278943371341">predicts</a> Pepe to overtake Shiba Inu based on Pepe&#8217;s market cap:trading volume ratio.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40876130/dogecoin-millionaire-highlights-pepe-and-dogecoin-as-two-biggest-meme-narratives-for-2025-">&#8216;Dogecoin Millionaire&#8217; Highlights Pepe and Dogecoin As &#8216;Two Biggest Meme Narratives For 2025,&#8217; Shiba Inu, Floki To Follow</a>
Why It Matters: IntoTheBlock data shows a 231.4% increase in large transaction volume and a 33.5% rise in daily active addresses. Transactions greater than $100,000 increased from 80 to 255 in the past two days.
Pepe's seven-day and 30-day gains stand at 13% and 8%, respectively. It has outperformed its rivals Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), up 3% and 6% over the past 30 days. In the past seven days, DOGE and SHIB are up 1% and 6%.
Pepe&#8217;s 24-hour trading volume at $1.7 billion exceeds that of both Dogecoin ($741.5 million) and Shiba Inu ($405 million) combined.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40881260/trader-shares-3-contrarian-takes-trump-meme-coin-an-obvious-buy-and-these-2-cryptos-are-de">Trader Shares &#8216;3 Contrarian Takes:&#8217; TRUMP Meme Coin &#8216;An Obvious Buy&#8217; And These 2 Cryptos Are &#8216;Deep Value&#8217; And Will Be &#8216;Outperforming Soon&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Pepe Leapfrogs Dogecoin, Shiba Inu In 30-Day Gains, Trading Volume: 'No One Is Bullish Enough,' Says Trader

CHPT

ChargePoint Says It Has Secured NEVI Award Funding To Proliferate EV Charging On California Highways

Asset Sales

NovaBay Pharmaceuticals Reaches Definitive Deal To Sell Avenova Assets For $9.5M, Expected To Close Q4 2024

KOPN

Kopin Corporation Announces Pricing Of $27M Public Offering Of Common Stock And Pre-funded Warrants; Closing Of The Offering Is Expected To Occur On Or About September 23

Global Engine Group Announces Pricing Of $8M Initial Public Offering At Public Offering Price Of $4.00 Per Share

Across the recent three months, 4 analysts have shared their insights on Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.0, a high estimate of $45.00, and a low estimate of $45.00. Marking an increase of 6.31%, the current average surpasses the previous average price target of $42.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833694_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Essential Utilities's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Fowler</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jonathan Reeder</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Essential Utilities. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Utilities compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Essential Utilities's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Essential Utilities's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WTRG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Utilities analyst ratings.</a>
<h2>Unveiling the Story Behind Essential Utilities</h2>
Essential Utilities is a Pennsylvania-based holding company for us water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Nearly three fourths of its water earnings come from Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. Essential exited its noncore competitive water and energy services businesses.
<h3>Essential Utilities: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Essential Utilities's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -0.53%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: Essential Utilities's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Essential Utilities's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Essential Utilities's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.44%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Essential Utilities's debt-to-equity ratio is below the industry average at 1.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WTRG

4 Analysts Have This To Say About Essential Utilities

Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $257.67, with a high estimate of $282.00 and a low estimate of $215.00. Marking an increase of 5.65%, the current average surpasses the previous average price target of $243.89. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833681_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Labcorp Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$249.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$261.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Labcorp Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Labcorp Holdings</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 6.17% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Labcorp Holdings's ROA excels beyond industry benchmarks, reaching 1.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Analyst Ratings For Labcorp Holdings

Analysts' ratings for Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $117.0, a high estimate of $135.00, and a low estimate of $103.00. This upward trend is apparent, with the current average reflecting a 13.15% increase from the previous average price target of $103.40.
<img src="https://www.benzinga.com/files/images/story/2024/1726833658_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Advanced Energy Indus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$128.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Advanced Energy Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Advanced Energy Indus's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Advanced Energy Indus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Advanced Energy Indus analyst ratings.</a>
<h2>Get to Know Advanced Energy Indus Better</h2>
Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in the United States, with the rest primarily from Asia and Europe.
<h3>Advanced Energy Indus: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Advanced Energy Indus's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -12.17%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Advanced Energy Indus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Advanced Energy Indus's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Advanced Energy Indus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.88, Advanced Energy Indus faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Analyst Expectations For Advanced Energy Indus's Future

In the last three months, 4 analysts have published ratings on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.25, a high estimate of $48.00, and a low estimate of $38.00. Surpassing the previous average price target of $37.00, the current average has increased by 14.19%.
<img src="https://www.benzinga.com/files/images/story/2024/1726833647_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Amkor Tech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Peter Peng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$48.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amkor Tech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amkor Tech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amkor Tech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amkor Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amkor Tech analyst ratings.</a>
<h2>Discovering Amkor Tech: A Closer Look</h2>
Amkor Technology Inc is a provider of outsourced semiconductor packaging and test services to integrated device manufacturers, fabless semiconductor companies, and contract foundries. The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
<h3>Financial Milestones: Amkor Tech's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Amkor Tech showcased positive performance, achieving a revenue growth rate of 0.24% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Amkor Tech's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 4.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Amkor Tech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.66%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Amkor Tech's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amkor Tech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

4 Analysts Assess Amkor Tech: What You Need To Know

During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $265.92, a high estimate of $300.00, and a low estimate of $230.00. Marking an increase of 2.28%, the current average surpasses the previous average price target of $260.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833637_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of IQVIA Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$256.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$288.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$242.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$251.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for IQVIA Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into IQVIA Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>Discovering IQVIA Hldgs: A Closer Look</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>Financial Insights: IQVIA Hldgs</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, IQVIA Hldgs showcased positive performance, achieving a revenue growth rate of 2.31% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): IQVIA Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 5.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IQVIA Hldgs's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 13 Analyst Recommendations For IQVIA Hldgs

Goldman Sachs analyst Jerry Revich maintains Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) with a Neutral and lowers the price target from $72 to $62.

Goldman Sachs Maintains Neutral on Terex, Lowers Price Target to $62

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $218.3, with a high estimate of $250.00 and a low estimate of $190.00. Observing a downward trend, the current average is 13.6% lower than the prior average price target of $252.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1726833616_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Charles River by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$203.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$191.00</td>
<td>$239.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$239.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Charles River. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Charles River's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Charles River's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charles River analyst ratings.</a>
<h2>Get to Know Charles River Better</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Charles River's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -3.19%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Charles River's net margin excels beyond industry benchmarks, reaching 8.77%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Charles River's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.12%, the company showcases effective utilization of assets.
Debt Management: Charles River's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Charles River In The Eyes Of 10 Experts

The Federal Reserve announced Wednesday<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead"> a deep 50 basis-point cut to its Fed funds rate, </a>which is likely to ease the pressure on consumers. An analyst, however, sees a return of recession along with stagnation.
What Happened: &#8220;Get ready for stagnation,&#8221; said GLJ Research&#8217;s Gordon Johnson, adding that, this is the &#8220;inflation is Transitory&#8221; mistake all over again. To make his case, he noted four corporate announcements suggesting the near could be challenging.
China Drags Skechers: Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), which designs, manufactures and distributes footwear, sees softness in China&#8217;s business. CFO John Vandemore said, at the Wells Fargo Consumer Conference, &#8220;We've definitely seen worse conditions unfold in China than we expected for the back half of the year, so I would expect the back of the year's going to be more disappointing than what we had originally thought.&#8221; The shares reacted with a sharp tumble on Thursday, settling down 9.62% to $61.56
Rough Road For Mercedes-Benz: Also German automaker Mercedes-Benz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>) late Thursday said its 2024 earnings before interest and taxes will likely come in &#8220;significantly below&#8221; the previous year, citing a further deterioration in the macroeconomic environment, mainly in China. The automaker also said it expects its adjusted return on sales to be between 7.5% and 8.5%, down from its earlier forecast of 10% to 11%. The company&#8217;s shares listed on the Frankfurt exchange fell nearly 7%.
See Also: <a href="https://www.benzinga.com/money/best-depression-stocks">Best Depression Stocks</a>
FedEx Doesn&#8217;t Deliver: Package-shipping company FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported first-quarter earnings that fell year-over-year and missed expectations. The company reduced the high end of the full-year adjusted operating income guidance. The predicament was blamed on circumspect consumers favoring cheaper services over pricey and speedier options. The stock fell over 13% in premarket trading on Friday.
Lennar&#8217;s Underwhelming Quarter: Homebuilder Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported roughly 8% revenue growth to $9.42 billion and earnings per share were up 10% but the average sales price of houses fell.
More Cuts At Warner Music: Entertainment and record-label company Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) said Thursday it plans to reduce its workforce by about 750 employees, representing 13% of its total headcount, more than the 10% expected earlier.
R-Word Still Floats Around: Chief Global Strategist of BCA Research Peter Berezin said in an X post that the 50 basis-point cut and another 50 bps reduction the central bank is penciling in before the year-end <a href="https://www.benzinga.com/news/earnings/24/09/40954521/wall-street-looks-to-pause-after-s-ps-record-performance-as-fed-rate-cut-euphoria-fades-and-hard-la">may not ensure a soft landing. </a>He pointed out to the previous two rate-cut cycles when recession followed following 100 basis-point cuts.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the S&amp;P 500 Index, fell 0.26% to $567.76, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data. </a>The ETF, however, is up nearly 21% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40948046/fedex-q1-earnings-revenue-miss-eps-miss-lowered-guidance-challenging-quarter">FedEx Q1 Earnings: Revenue Miss, EPS Miss, Lowered Guidance — &#8216;Challenging Quarter&#8217;</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Earnings

Equities

Economics

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

Brace For Stagflation After Fed's Benevolence, Warns Analyst, Raising 5 Corporate Red Flags: 'Inflation Is Transitory Mistake All Over Again'

Evercore ISI Group analyst Greg Melich maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Outperform and lowers the price target from $3900 to $3350.

Evercore ISI Group Maintains Outperform on AutoZone, Lowers Price Target to $3350

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics has reported encouraging outcomes from a Phase 2 trial of CM-101, showca...

Chemomab's CM-101 Shows Promise in PSC Trial

Chemomab falls on private placement despite mid-stage win for lead asset

Chemomab Therapeutics regains compliance with Nasdaq

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating yesterday. Michael Okunewitch's ratin...

Promising Phase 2 Results and Strong Financials Underpin Buy Rating for Chemomab Therapeutics

Chemomab Therapeutics GAAP EPS of -$0.01

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics Ltd. has released its unaudited interim condensed consolidated financial...

Chemomab Therapeutics Reports Mid-Year Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Oppenheimer analyst Jeff Jones maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $13.00. Th...

Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Strong Buy Rating on Robust Financials and Positive Clinical Trial Outcomes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Press Releases

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Chemomab Therapeutics

Chemomab Therapeutics (CMMB) Forecast

Chemomab Therapeutics (NASDAQ:CMMB) Stock, Quote.Headers.trade-ideas